Lisuride plus selegiline in the treatment of early Parkinson's disease

G. Nappi, E. Martignoni, R. Horowski, C. Pacchetti, E. Rainer, P. Bruggi, I. Runge

Research output: Contribution to journalArticlepeer-review


We treated 20 early Parkinson's disease subjects with the dopamine agonist lisurgide in combination with the MAO-B inhibitor selegiline (L-deprenyl). We started with lisuride alone for one month, then we added selegiline versus placebo to lisuride in double-blind conditions for 3 months; finally all patients received lisuride and selegiline for another 3 months. Lisuride alone (1.43 ± 0.10 mg) significantly improved PD. When selegiline (10 mg/day) was added in the double-blind phase the mean lisuride dosage could be reduced by 22.8% without deterioration of the clinical effects, and the same occurred in the former placebo group when selegiline was added. The combination of both drugs was well tolerated. These data are of interest for the interpretation of the effects of selegiline.

Original languageEnglish
Pages (from-to)407-410
Number of pages4
JournalActa Neurologica Scandinavica
Issue number6
Publication statusPublished - 1991


  • L-deprenyl
  • Lisuride
  • Parkinson's disease
  • Selegiline

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Lisuride plus selegiline in the treatment of early Parkinson's disease'. Together they form a unique fingerprint.

Cite this